Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

Staphylococcus aureus

  • <em>In Vivo</em> Pharmacodynamic Evaluation of Omadacycline against <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> in the Neutropenic Mouse Pneumonia Model
    Experimental Therapeutics
    In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model

    Omadacycline is an effective therapy for community-acquired bacterial pneumonia (CABP). Given its potent activity against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA), we sought to determine the pharmacodynamic activity and target pharmacokinetic/...

    Alexander J. Lepak, Miao Zhao, Karen Marchillo, Jamie VanHecker, David R. Andes
  • Exebacase Demonstrates <em>In Vitro</em> Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span>
    Experimental Therapeutics
    Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus

    In vitro synergy between an antimicrobial protein lysin (cell wall hydrolase) called exebacase and each of 12 different antibiotics was examined against Staphylococcus aureus isolates using a nonstandard medium approved for exebacase susceptibility testing by the Clinical and Laboratory Standards Institute. In the checkerboard assay format, fractional...

    Aubrey Watson, Karen Sauve, Cara Cassino, Raymond Schuch
  • Efficacy of Bacteriophages in a <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Nondiabetic or Diabetic Foot Infection Murine Model
    Experimental Therapeutics
    Efficacy of Bacteriophages in a Staphylococcus aureus Nondiabetic or Diabetic Foot Infection Murine Model

    This study investigated the in vivo efficacy of three bacteriophages combined compared with linezolid in two mouse models (nondiabetic and diabetic) of Staphylococcus aureus foot infection. In both models, a single injection of bacteriophages in the hindpaw showed significant antibacterial efficacy. Linezolid was as effective as bacteriophages in nondiabetic...

    S. Albac, M. Medina, D. Labrousse, D. Hayez, D. Bonnot, N. Anzala, F. Laurent, T. Ferry, A. Dublanchet, P. Chavanet, C. Fevre, D. Croisier
  • A Prospective Cohort Study of Durations of <em>Staphylococcus aureus</em> Bacteremia According to Different Phenotypes and a New Concept of Persistent Bacteremia
    Epidemiology and Surveillance
    A Prospective Cohort Study of Durations of Staphylococcus aureus Bacteremia According to Different Phenotypes and a New Concept of Persistent Bacteremia

    The purpose of this study was to describe and compare the duration of Staphylococcus aureus bacteremia (SAB) according to methicillin resistance and the primary foci of infection. We also aimed to newly define persistent SAB considering these results. Nonduplicated episodes of SAB in patients aged ≥15 years from 14 hospitals in the Republic of Korea were analyzed...

    Chang Kyung Kang, Kyoung-Ho Song, Seong Eun Kim, Eu Suk Kim, Wan Beom Park, Kyung-Hwa Park, Shin Hye Chun, Shinwon Lee, Chong Rae Cho, Seung Ji Kang, Myoung-don Oh, Yeon-Sook Kim, Sun Hee Lee, Yee Gyung Kwak, Hee-Chang Jang, Chung-Jong Kim, Young Keun Kim, Ji-Hwan Bang, Sungmin Kiem, Ki Tae Kwon, Younghee Jung, Yu Min Kang, Sook-In Jung, Hong Bin Kim, the Korea Infectious Diseases (KIND) Study Group
  • Open Access
    Nitroxide Functionalized Antibiotics Are Promising Eradication Agents against <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Biofilms
    Experimental Therapeutics
    Nitroxide Functionalized Antibiotics Are Promising Eradication Agents against Staphylococcus aureus Biofilms

    Treatment of biofilm-related Staphylococcus aureus infections represents an important medical challenge worldwide, as biofilms, even those involving drug-susceptible S. aureus strains, are highly refractory to conventional antibiotic therapy. Nitroxides were recently shown to induce the dispersal of...

    Anthony D. Verderosa, Rabeb Dhouib, Kathryn E. Fairfull-Smith, Makrina Totsika
  • Open Access
    RexAB Is Essential for the Mutagenic Repair of <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> DNA Damage Caused by Co-trimoxazole
    Mechanisms of Action: Physiological Effects
    RexAB Is Essential for the Mutagenic Repair of Staphylococcus aureus DNA Damage Caused by Co-trimoxazole

    Co-trimoxazole (SXT) is a combination therapeutic that consists of sulfamethoxazole and trimethoprim that is increasingly used to treat skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA). However, the use of SXT is limited to the treatment of low-burden, superficial...

    Rebecca S. Clarke, Maya S. Bruderer, Kam Pou Ha, Andrew M. Edwards
  • Roles of Lytic Transglycosylases in Biofilm Formation and β-Lactam Resistance in Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span>
    Mechanisms of Resistance
    Roles of Lytic Transglycosylases in Biofilm Formation and β-Lactam Resistance in Methicillin-Resistant Staphylococcus aureus

    Staphylococcus aureus is responsible for numerous community outbreaks and is one of the most frequent causes of nosocomial infections with significant morbidity and mortality. While the function of lytic transglycosylases (LTs) in relation to cell division, biofilm formation, and antibiotic resistance has been determined for several bacteria, their role in...

    Anne-Aurelie Lopes, Yutaka Yoshii, Satomi Yamada, Mari Nagakura, Yuki Kinjo, Yoshimitsu Mizunoe, Ken-ichi Okuda
  • Evolution of a 72-Kilobase Cointegrant, Conjugative Multiresistance Plasmid in Community-Associated Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> Isolates from the Early 1990s
    Mechanisms of Resistance
    Evolution of a 72-Kilobase Cointegrant, Conjugative Multiresistance Plasmid in Community-Associated Methicillin-Resistant Staphylococcus aureus Isolates from the Early 1990s

    Horizontal transfer of plasmids encoding antimicrobial resistance and virulence determinants has been instrumental in Staphylococcus aureus evolution, including the emergence of community-associated methicillin-resistant S. aureus (CA-MRSA). In the early 1990s, the first CA-MRSA strain isolated in...

    Karina Yui Eto, Neville Firth, Amy M. Davis, Stephen M. Kwong, Marcelina Krysiak, Yung Thin Lee, Frances G. O’Brien, Warren B. Grubb, Geoffrey W. Coombs, Charles S. Bond, Joshua P. Ramsay
  • Toxic Shock Syndrome Toxin 1-Producing Methicillin-Resistant <span class="named-content genus-species" id="named-content-1">Staphylococcus aureus</span> of Clonal Complex 5, the New York/Japan Epidemic Clone, Causing a High Early-Mortality Rate in Patients with Bloodstream Infections
    Epidemiology and Surveillance
    Toxic Shock Syndrome Toxin 1-Producing Methicillin-Resistant Staphylococcus aureus of Clonal Complex 5, the New York/Japan Epidemic Clone, Causing a High Early-Mortality Rate in Patients with Bloodstream Infections

    This study was performed to evaluate the clinical impacts of putative risk factors in patients with Staphylococcus aureus bloodstream infections (BSIs) through a prospective, multicenter, observational study. All 567 patients with S. aureus BSIs that occurred during a 1-year period in six general...

    Dokyun Kim, Jun Sung Hong, Eun-Jeong Yoon, Hyukmin Lee, Young Ah Kim, Kyeong Seob Shin, Jeong Hwan Shin, Young Uh, Jong Hee Shin, Yoon Soo Park, Seok Hoon Jeong
  • <em>In Vitro</em> Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection
    Susceptibility
    In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection

    The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin MICs of 0.25 to 1 μg/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of ≤1 μg/ml may be too high.

    Mariana Albano, Melissa J. Karau, Kerryl E. Greenwood-Quaintance, Douglas R. Osmon, Caitlin P. Oravec, Daniel J. Berry, Matthew P. Abdel, Robin Patel

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 72
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596